Massachusetts Puts Nearly $40 Million Behind Biotech’s Most Radical Product, a Payroll

The next great Massachusetts life-sciences platform may require a badge printer. This is less glamorous than a molecule rotating above a conference stage, but the badge printer has one enviable feature: it usually indicates someone actually works there.

On September 28, Governor Maura Healey announced nearly $40 million in tax incentives for 38 life-sciences companies, tied to 1,644 expected new jobs. The announcement took place at SMC in Devens. According to the Massachusetts Life Sciences Center, 31 recipients are expanding outside Boston and Cambridge, representing 71 percent of the anticipated jobs.

That geography is the story. Greater Boston’s scientific reputation is useful, but a reputation cannot staff a manufacturing line. This round is a meaningful, conditional bet on turning the region’s technical depth into lasting operations. The word “conditional” deserves its own chair at the ribbon-cutting.

Kendall Square does not own the entire map

The award table gives Insulet $10 million for 250 jobs in Acton, Lila Sciences $3.6 million for 200 jobs in Cambridge, Bristol Myers Squibb $2.875 million for 125 jobs in Devens, and SMC $1.35 million for 54 jobs there. Those are commitments, not a report that everyone has already arrived for orientation.

There is something healthy about an ecosystem story that requires several highway exits to explain. If success means useful technology becoming a durable business, the map needs room for production, testing, suppliers, and the people who keep equipment behaving after the visiting delegation leaves.

Our earlier coverage of Massachusetts’ Business Builds capital grants followed the same problem from the equipment side. Facilities and machinery are an essential stage between an impressive prototype and something a customer can order repeatedly. Hiring incentives approach that transition through the workforce. A building and a payroll are complementary forms of evidence.

The robots have a People department

Lila offers the most delicious tension. A company developing autonomous science has committed to adding 200 people. Somewhere, a keynote slide about the end of work has quietly requested a revision.

In its description of the technology, Lila connects scientific reasoning models with tools, laboratory automation, and experimental verification. The proposed loop is straightforward: generate a hypothesis, design and execute a test, evaluate the result, and use that evidence to improve what happens next. Software is meant to learn from physical experiments, where reality gets a vote.

That is a serious technical proposition. It also helps explain why laboratory AI can require an organization full of humans. Someone must build the instruments, integrate the software, decide whether measurements are trustworthy, and translate a promising result into work another team can reproduce. Autonomy changes tasks; it does not make the surrounding institution evaporate.

Lila’s broad scientific-superintelligence claims remain the company’s ambitions, not something established by a tax award. The incentive is a hiring commitment with public support. It is neither a scientific benchmark nor evidence that a discovery will become a medicine.

The distinction echoes Transfyr’s effort to capture how laboratory work actually happens. Better scientific automation depends on understanding execution, including the details that never quite make it into a polished protocol. Boston has found a way to make even a robot need onboarding. On this occasion, that is a compliment.

Acton brings something you can manufacture

Insulet gives the package a different kind of substance. Its corporate locations page identifies Acton as both its headquarters and the site of a highly automated manufacturing facility. This is an existing physical operation, not a speculative pin dropped onto an economic-development map.

The company’s 2025 sustainability report describes Omnipod products that deliver insulin through a wearable, tubeless Pod. The technical point is that an apparently simple patient-facing object rests on manufacturing expertise and continuity of supply. An elegant device becomes useful through reliable production.

For readers outside Massachusetts, this is the part worth watching. A region can invent medical technology and still need to work at retaining the industrial capabilities around it. The practical question is whether public support helps deepen those capabilities enough to justify its cost.

SiliconSnark’s look at Azenta’s sample-management infrastructure made a related point: life sciences depends on equipment and services that rarely receive the heroic lighting. Manufacturing, storage, traceability, and quality are how scientific promises acquire an address and a delivery schedule.

Please retain your receipts and your employees

The MLSC’s published program rules require participating companies to commit to hiring during 2026 and retaining those jobs through December 31, 2028. Annual reports track hiring and retention against commitments. The program says companies that fail to comply face decertification and must return incentives to the Department of Revenue.

That gives the announcement a useful test beyond applause. Did the positions materialize? Did they remain? Can the state show what happened against each commitment?

Even successful compliance would leave a harder question: how much hiring happened because of the incentive, rather than receiving support for plans already likely to proceed? The announcement alone cannot answer that. Nor should a count of promised jobs be mistaken for a complete accounting of public return.

Those questions are reasons to track the program carefully, not reasons to dismiss the work. Long-lived scientific and manufacturing operations can be valuable neighbors. The public deserves evidence that its contribution helped produce them.

A useful win, pending the attendance sheet

My verdict is positive: a concrete, measurable ecosystem investment with a better premise than another declaration that Massachusetts is very smart. The mix connects experimental AI, established medical technology, and operations beyond the two cities that tend to dominate the conversation.

The next milestone should be wonderfully uncinematic: verified hiring, retained jobs, and teams doing useful work. Boston can keep the ambitious science. This time, let the badge printer deliver the closing argument.